What is BPC-157? Human studies and evidence limits

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids. In the literature it is referred to as the "stable gastric pentadecapeptide," and it is described as a partial sequence derived from a protein, "body protection compound" (BPC), that researchers identified in gastric juice. As a laboratory reagent it is manufactured by solid-phase peptide synthesis and supplied lyophilised (freeze-dried), like most laboratory peptides.

Origin in the literature

The bulk of the BPC-157 research corpus originates with a long-running programme led by Predrag Sikiric and colleagues, who situate the peptide within what they call the "cytoprotection" concept — a line of gastrointestinal research concerned with how the stomach and its lining protect themselves. In their reviews, BPC-157 is presented as a candidate mediator within that framework, and as a compound studied across a range of injury models. This body of work is the reason the peptide is so consistently described as "stable" and "gastric" in its name: those descriptors come from where and how it was first characterised.

Research areas described in published reviews

Published review articles group the preclinical BPC-157 literature into a few broad areas. The following summarises what those reviews describe as having been studied — overwhelmingly in cell and animal models — not established effects in people.

Gastrointestinal tract

The earliest and largest cluster concerns the gastrointestinal tract. A 2011 review in Current Pharmaceutical Design describes BPC-157 studies across the GI tract, including work on the healing of various fistulas and on interactions with signalling systems such as the nitric oxide pathway, in rat models (Sikiric et al., 2011).

Wound healing

A 2021 review in Frontiers in Pharmacology collates preclinical studies grouped under wound healing, describing the peptide's investigation in models of tissue repair and bleeding disorders (Seiwerth et al., 2021). As with the rest of the corpus, these are laboratory and animal studies.

Musculoskeletal soft tissue

A 2019 review in Cell and Tissue Research focuses on musculoskeletal soft tissue — tendon, ligament, and skeletal muscle — and summarises the animal-model literature in that area. The authors described human clinical trials as pending in 2019 (Gwyer, Wragg & Wilson). That historical assessment predates the small human reports discussed in the next section.

Study stage and the evidence gap

Yes, BPC-157 has been studied in humans, but the published studies are small and uncontrolled. Most of the literature remains preclinical. Examples of human reports include:

• Bladder-pain pilot (2024): 12 women with interstitial cystitis reported symptom improvement after a procedure involving BPC-157. There was no comparison group, so the study cannot establish that BPC-157 caused the improvement. Read the original study.
• Intravenous safety pilot (2025): two adults who had previously received BPC-157 were monitored over three days. The authors reported no side effects or concerning changes in the measured blood markers. Two selected participants and short follow-up cannot establish general safety, detect uncommon harms, or answer questions about long-term use. Read the original study.

These reports are preliminary observations, not large randomised trials. They do not establish that BPC-157 heals injuries in people, define an effective clinical dose, or show that different formulations and routes are equivalent. The BPC-157 product page describes the laboratory reagent and its documentation; it is not evidence of clinical benefit.

Stability and format notes

The peptide's name advertises its defining physicochemical property: the literature describes it as notably stable, including in aqueous solution and, in the source reviews, in gastric juice — a robustness that is unusual for a small peptide and is part of why it attracted research interest. For laboratory handling, BPC-157 behaves like other lyophilised laboratory peptides:

• Format: supplied as a lyophilised powder, reconstituted into a stock solution with bacteriostatic water or another appropriate diluent when a study requires it.
• Storage: the dry solid is far more stable than the solution; refrigerate or freeze per general peptide practice, and keep away from light and heat.
• In solution: aliquot and freeze to avoid repeated freeze-thaw, and follow the same anti-degradation habits (cold, dark, gentle handling) that apply to peptides generally.

The site's reconstitution calculator handles the concentration arithmetic and sets out the general handling procedure behind it. Relative stability does not exempt any peptide from careful storage — it simply widens the margin.

Regulatory status

BPC-157 is not an authorised medicine. It has no marketing authorisation in Europe or Ireland, and it is not an approved therapeutic product anywhere that would place it in the licensed-medicine category. It is studied as a research compound. Because it corresponds to no authorised medicine, it is supplied strictly as a laboratory reagent, described factually and without human-use claims — the same posture set out in the research-use policy. Anyone weighing the regulatory position for a specific purpose should consult the relevant competent authority or a qualified professional.

How to read this literature

Three habits keep interpretation honest:

• Distinguish model from meaning. "Studied in a rat model" is a description of an experiment, not a promise about outcomes in people.
• Weigh source diversity. A literature drawn largely from a few related groups is a reason for measured interpretation until independent replication accumulates.
• Read primary sources. The reviews cited below are open entry points into the underlying studies; the abstracts and full texts are the authoritative record, not third-hand summaries.

Sources

Review articles and primary human studies indexed on PubMed. The human-study records were checked on 23 October 2026.

Frequently asked